Paushak Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Mon Apr 20 2026

Paushak (NSE: PAUSHAK) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Paushak trading at Rs 4,200 — against a 52-week high of Rs 6,800 and a 1-year return of -32% — the Q4 FY26 results will be a pivotal event for investors tracking the Specialty Chemicals sector.

Analyst estimates for Q4 FY26 revenue stand at Rs 88–102 Cr, with PAT expectations of Rs 18–26 Cr and margin projections of EBITDA 25–32%. This article covers the Paushak Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings, and answers to the most commonly searched investor questions.

Get free investment predictions on Univest.

Table of Contents

Paushak Q4 Results 2026 Date

Company	Q4 FY26 Results Date	Sector
TCS	April 9, 2026	IT Services
Infosys	April 23, 2026	IT Services
Paushak	May 2026 (Expected)	See article

Paushak has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 4,200, investors will closely watch this announcement for revenue growth confirmation and FY27 guidance.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Paushak, operating in the Specialty Chemicals sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management’s strategic initiatives are delivering measurable financial outcomes.

At a 1-year return of -32%, the Q4 FY26 results and FY27 guidance commentary will be critical in determining whether the stock can recover toward its 52-week high of Rs 6,800. Investors will focus on order book updates, margin trajectory, and management tone — positive surprises on multiple parameters could drive a meaningful re-rating.

Paushak Q4 FY26 Earnings Estimates

Paushak Q4 FY26 Analyst Estimates at a Glance Source MOFSL, YES Securities, JM Financial

Access premium SEBI-registered research on Univest.

Analysts covering Paushak have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 88–102 Cr, PAT of Rs 18–26 Cr, and margins of EBITDA 25–32%. These projections incorporate Q4 seasonal strength and ongoing business improvements.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate
Revenue	Rs 78 Cr	Rs 88–102 Cr
PAT	Rs 15 Cr	Rs 18–26 Cr
Margin	EBITDA 27.5%	EBITDA 25–32%
Growth Driver	Base quarter	Recovery catalyst
Dividend	Rs 50 per share	Rs 25–40 per share

Beyond headline numbers, investors should monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print — rather than one inflated by non-operational items — carries greater weight with long-term investors.

Screen Paushak fundamentals on Univest Screener.

5 Key Factors That Will Drive Paushak Q4 FY26 Performance

Phosgene Chemistry Monopoly

Paushak is one of very few companies in India licensed to handle phosgene — an extremely hazardous industrial gas used in pharmaceutical synthesis. This creates a near-monopoly moat for the company in India’s phosgene-based specialty chemical market. Q4 FY26 revenue growth reflects the growing demand from domestic and global pharma clients for phosgene-derived intermediates.

CDMO and Pharma Intermediate Exports

Paushak’s customer base includes leading global pharmaceutical companies sourcing complex phosgene-based intermediates for drug synthesis. Q4 FY26 export revenue — representing 55–60% of total revenues — will reflect the health of global pharma CDMO demand. Any new long-term supply agreement with a global pharma company would be a significant re-rating catalyst.

Margin Sustainability at 25–32%

Paushak’s high EBITDA margins — among the highest in Indian specialty chemicals — reflect the combination of hazardous chemistry expertise, limited competition, and premium pricing power. Q4 FY26 will test whether these margins can be sustained despite input cost pressures and any customer renegotiations.

Capacity Expansion and Revenue Scalability

Paushak has been investing in capacity additions to meet growing pharma intermediate demand. Q4 FY26 will reflect the initial revenue contribution from newly commissioned capacity. Management commentary on timeline to full utilisation of new capacity will inform FY27 revenue estimates.

Ahmedabad Site Safety and Regulatory Compliance

Paushak’s Vadodara manufacturing facility operates under strict safety and environmental regulations given the hazardous nature of phosgene chemistry. Any safety incident or regulatory compliance issue would immediately halt operations and materially impact revenue. Q4 FY26 safety record will be an important operational indicator.

5 Risks to Watch in Paushak Q4 FY26

Single-Product Concentration

Paushak’s revenues are highly concentrated in phosgene-based chemistry. While the moat is strong, a technological disruption that enables pharma companies to bypass phosgene chemistry would structurally threaten the business.

Hazardous Process Risk

Phosgene is one of the most dangerous industrial chemicals. Any accident at Paushak’s plant would halt operations, create regulatory scrutiny, and generate significant liability — both financial and reputational.

Customer Concentration in Pharma

Paushak’s revenues are concentrated in a few large global pharma customers. Loss of a key customer — due to competitive sourcing or supply chain restructuring — would materially impact revenues.

Regulatory Approval Risk

Paushak’s products are used in pharma manufacturing subject to stringent regulatory approvals. Any GMP compliance issue or import alert from US FDA or EU EMA would disrupt supply to regulated market customers.

Premium Valuation Vulnerability

Paushak trades at a significant premium to specialty chemical peers based on its unique business model. Any earnings disappointment — even a temporary one — could trigger disproportionate valuation compression given the premium multiple.

Paushak Share Price and Analyst Ratings

Paushak Share Price & Analyst Ratings | Source: NSE/BSE, Broker Notes

Paushak is trading at Rs 4,200 as of early April 2026, against a 52-week high of Rs 6,800 and 52-week low of Rs 3,500. Market cap stands at Rs 1,850 Cr. The 1-year return of -32% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on recovery pace and FY27 earnings potential.

Brokerage	Rating	Target Price	Thesis
MOFSL	Buy	Rs 5,500	Phosgene chemistry moat
YES Securities	Buy	Rs 5,800	High-margin specialty
Kotak Inst.	Buy	Rs 5,200	CDMO optionality

Download the Univest iOS App or Univest Android App to track Paushak’s live price and receive real-time Q4 result alerts.

Conclusion

Paushak Q4 FY26 results will demonstrate the sustained power of its phosgene chemistry moat. At Rs 4,200, the stock is 38% below its 52-week high, with the market pricing in some execution uncertainty. Revenue toward Rs 95 Cr with PAT above Rs 22 Cr would confirm the business is on track. Any CDMO contract announcement with a global pharma company would be the most powerful potential catalyst. Consult a SEBI-registered advisor before investing.

This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.

For more Q4 FY26 previews visit Univest Blogs.

Frequently Asked Questions

What is the Paushak Q4 results 2026 date?

Paushak Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements for the quarter ended March 31, 2026.

What is the Paushak Q4 FY26 PAT estimate?

Analysts estimate Paushak Q4 FY26 PAT in the range of Rs 18–26 Cr, on revenue of Rs 88–102 Cr and margin of EBITDA 25–32%. Actual results may differ from these estimates.

What is Paushak’s share price ahead of Q4 results?

Paushak shares are trading at approximately Rs 4,200 as of early April 2026. The 52-week high is Rs 6,800 and 52-week low is Rs 3,500. The one-year return is -32% and market cap stands at Rs 1,850 Cr.

Will Paushak declare a dividend in Q4 2026?

Paushak is expected to consider Rs 25–40 per share at the Q4 FY26 board meeting on May 2026 (Expected). The dividend decision reflects management’s confidence in FY26 free cash flow generation.

Which analysts have a Buy rating on Paushak?

MOFSL (target Rs 5,500), YES Securities (target Rs 5,800), Kotak Inst. (target Rs 5,200) ahead of Q4 FY26 results.

What were Paushak Q3 FY26 results?

In Q3 FY26, Paushak reported revenue of Rs 78 Cr and PAT of Rs 15 Cr with margins at EBITDA 27.5%. These provided the base for Q4 FY26 analyst estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026 — full preview at TCS Q4 Results 2026. Infosys announced results on April 23, 2026.

Is Paushak a good investment ahead of Q4 results?

Paushak at Rs 4,200 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.